Hot Pursuit     29-Sep-21
Morepen Lab gains on plan to hive off medical devices biz into subsidiary
Morepen Laboratories rose 2.05% to Rs 57.20 after the company announced plans to carve out its point of care medical devices business into a newly incorporated wholly-owned subsidiary Morepen Devices.
In a regulatory filing on Wednesday, the company said that shareholders approved the plan on 28 September 2021 in the 36th Annual General Meeting (AGM).

The transfer of the business would happen as per terms of the business transfer agreement to be signed between both the companies.

The medical devices (POC) business has achieved a leadership position in the market. It recorded a growth of 71% in the financial year ending March 2021. In Q1 FY22, POC business recorded a growth of 187%.

Growing health concerns have pushed the average usage of diagnostics devices during last one and half year. This boosted sales revenues particularly in last two years.

"We expect the growth drivers will continue fuelling the higher consumption levels in the coming times," the company said in a statement.

The POC medical devices business is marketed under the brand “Dr. Morepen”. It sells devices like glucometer, blood pressure monitor and other home care products.

The company aims to strengthen further over the next 2-3 years. The hiving off of the POC business in a separate entity is a first step towards building a global brand. The new devices company will be scaling up its R&D teams.

It also plans to acquire all relevant certifications of its manufacturing facilities and products for exporting them to regulated markets in Europe and North America. It aims to become a hub for manufacturing Point of care medical devices for the Global market.

The new entity plans to deploy more resources on the R&D, backwards integration of core technologies like making enzymes/proteins.

The new company will be able to raise capital to fund its growth and make investment on innovation, research, capacity expansion and promotion of its products. The proposed segregation will give the clarity to the working teams, trade, customers and other stakeholders. The company said it expects a huge value creation for the shareholders.

On a consolidated basis, Morepen Laboratories reported 57.31% rise in net profit to Rs 30.47 crore on 50.10% rise in net sales to Rs 386.73 crore in Q1 FY22 over Q1 FY21.

Morepen Laboratories is a pharmaceutical and healthcare products company. It is a leading manufacturer of high-quality APIs, home diagnostics, formulations and OTC products in north India.

Previous News
  Morepen Laboratories consolidated net profit rises 147.23% in the June 2024 quarter
 ( Results - Announcements 12-Aug-24   10:45 )
  Morepen Laboratories consolidated net profit declines 81.52% in the June 2022 quarter
 ( Results - Announcements 29-Jul-22   14:42 )
  Morepen Laboratories standalone net profit declines 27.96% in the March 2023 quarter
 ( Results - Announcements 16-May-23   17:18 )
  Morepen Laboratories schedules AGM
 ( Corporate News - 12-Sep-24   16:01 )
  Morepen Laboratories consolidated net profit rises 93.70% in the June 2018 quarter
 ( Results - Announcements 14-Aug-18   14:46 )
  Morepen Laboratories consolidated net profit rises 57.31% in the June 2021 quarter
 ( Results - Announcements 27-Jul-21   13:19 )
  Morepen Laboratories consolidated net profit rises 142.83% in the March 2021 quarter
 ( Results - Announcements 04-May-21   12:07 )
  Morepen Laboratories reports net loss of Rs 15.66 crore in the September 2008 quarter
 ( Results - Announcements 23-Oct-08   09:50 )
  Morepen Laboratories EGM scheduled
 ( Corporate News - 26-Feb-24   10:28 )
  Morepen Laboratories to announce Quarterly Result
 ( Corporate News - 23-Jul-22   14:02 )
  Morepen Laboratories standalone net profit declines 37.72% in the September 2019 quarter
 ( Results - Announcements 16-Nov-19   15:05 )
Other Stories
  Avantel Q2 PAT jumps 42% YoY to Rs 23 cr
  05-Oct-24   17:03
  Equitas SFB total deposits jump 29% YoY in Q2 FY25
  05-Oct-24   16:28
  Ujjivan SFB total deposits rises 17% in Q2 FY25
  05-Oct-24   15:34
  L&T Finance retail disbursements jump 12% YoY in Q2 FY25
  05-Oct-24   14:31
  Bandhan Bank records over 21% YoY jump in loan book during Q2 FY25; deposits at Rs 1.42 lakh crore
  05-Oct-24   13:32
  Lupin's Pune-based biotech facility gets 5 observations from US FDA
  05-Oct-24   13:20
  Macrotech Developers pre-sales jumps 21% YoY in Q2 FY25
  05-Oct-24   09:04
  UCO Bank’s total advances jump 19% YoY in Q2 FY25
  04-Oct-24   15:15
  Vakrangee Ltd leads losers in 'A' group
  04-Oct-24   15:00
  Kamdhenu Ventures Ltd leads losers in 'B' group
  04-Oct-24   14:45
Back Top